$460 Million is the total value of New Leaf Venture Partners, L.L.C.'s 19 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DCPH | Sell | DECIPHERA PHARMACEUTICALS INC | $129,878,000 | +24.5% | 2,086,723 | -32.1% | 28.22% | -10.6% |
| ARVN | ARVINAS INC | $93,810,000 | +90.7% | 2,283,048 | 0.0% | 20.38% | +37.0% | |
| SRRA | SIERRA ONCOLOGY INC | $68,760,000 | +3408.2% | 5,020,446 | 0.0% | 14.94% | +2419.1% | |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $50,103,000 | -11.1% | 914,625 | -54.2% | 10.88% | -36.2% |
| HARP | HARPOON THERAPEUTICS INC | $43,208,000 | +8.3% | 2,921,405 | 0.0% | 9.39% | -22.2% | |
| ARAV | Sell | ARAVIVE INC | $12,938,000 | +77.7% | 946,423 | -2.5% | 2.81% | +27.7% |
| APTX | APTINYX INC | $11,252,000 | -2.0% | 3,290,079 | 0.0% | 2.44% | -29.6% | |
| ALEC | ALECTOR INC | $11,020,000 | +19.5% | 639,569 | 0.0% | 2.39% | -14.2% | |
| ITRM | ITERUM THERAPEUTICS PLC | $6,553,000 | -22.0% | 1,456,303 | 0.0% | 1.42% | -44.0% | |
| AVRO | AVROBIO INC | $6,352,000 | +42.5% | 315,550 | 0.0% | 1.38% | +2.4% | |
| STIM | Sell | NEURONETICS INC | $4,666,000 | -59.2% | 1,039,285 | -24.5% | 1.01% | -70.7% |
| CHMA | CHIASMA INC | $3,649,000 | +0.2% | 735,700 | 0.0% | 0.79% | -28.0% | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $3,585,000 | -1.0% | 335,000 | +17.5% | 0.78% | -28.9% |
| CRNX | CRINETICS PHARMACEUTICALS INC | $3,538,000 | +66.8% | 141,000 | 0.0% | 0.77% | +19.8% | |
| OBSV | OBSEVA SA | $3,440,000 | -54.1% | 900,501 | 0.0% | 0.75% | -67.1% | |
| NERV | MINERVA NEUROSCIENCES INC | $3,196,000 | -8.3% | 449,500 | 0.0% | 0.69% | -34.2% | |
| CMRX | CHIMERIX INC | $2,741,000 | -13.6% | 1,350,000 | 0.0% | 0.60% | -38.0% | |
| UMRX | UNUM THERAPEUTICS INC | $1,293,000 | -50.0% | 1,795,545 | 0.0% | 0.28% | -64.1% | |
| PDSB | PDS BIOTECHNOLOGY CORP | $311,000 | -21.5% | 117,242 | 0.0% | 0.07% | -43.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.